Oncología Médica Traslacional y Terapia Individualizada del Cáncer

García-Alfonso, P; Elez, E; Soto-Alsar, J; Páez, D; Fernández-Montes, A; Graña, B; Salud, A; Yubero, A; Gómez-España, MA; Macías, I; Quintero, G; López-López, C; Fernández-Rodríguez, T; Grávalos, C; González-Flores, E; Guix, M; Paredes, BG; Reina, JJ; Mowbray, JRR; Sastre, J; Aranda, E.

Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial

Esmo Open. 2024; 9(12): [doi:10.1016/j.esmoop.2024.103986]

de la Haba-Rodríguez, JR; Mínguez, P; Rojo, F; Martín, M; Alba, E; Servitja, S; Prat, A; Pérez-Fidalgo, JA; Gavilá, J; Morales, C; Rodriguez-Lescure, A; Herrero, C; Peña-Enriquez, R; Herranz, J; Hernando, C; Hernández-Blanquisett, A; Guil-Luna, S; Martinez, MT; Blanch, S; Caballero, R; Martín, N; Pollán, M; Guerrero-Zotano, A; Bermejo, B.

Gestational breast cancer: distinctive molecular and clinico-epidemiological features

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA. 2024; 29(1): Nº de citas: 1 [doi:10.1007/s10911-024-09571-3]

Frazer, R; Arranz, JA; Estévez, SV; Parikh, O; Krabbe, LM; Vasudev, NS; Doehn, C; Marschner, N; Waddell, T; Ince, W; Goebell, PJ.

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis

Current Oncology Reports. 2024; 26(12): 1639-1650 Nº de citas: 1 [doi:10.1007/s11912-024-01613-7]

García-Alfonso, P; Jimenez-Fonseca, P; Soto-Alsar, J; Baraibar, I; Santos, C; La Casta, A; Ghanem, I; Cortijo, G; Méndez, A; Pazo-Cid, R; Vera, R; Melián, M; Alcaide, J; Graña, B; Páez, D; Gallego, I; Lobo, M; Borregón, M; Montes, A; de Castro, E; Carmona-Bayonas, A; Aranda, E.

Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study

ONCOLOGIST. 2024; 30(8): Nº de citas: 3 [doi:10.1093/oncolo/oyae300]

Weber, J; Del Vecchio, M; Mandalá, M; Gogas, H; Arance, AM; Dalle, S; Cowey, CL; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Márquez-Rodas, I; Butler, MO; Di Giacomo, AM; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, A; Fecher, LA; Millward, M; Khushalani, NI; Queirolo, P; Long, GV; Lobo, M; Askelson, M; Ascierto, PA; Larkin, J.

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(31): 3702 Nº de citas: 2 [doi:10.1200/JCO.23.01448]

Weichenthal, M; Mangana, J; Gavrilova, I; Lugowska, I; Shalamanova, GK; Kandolf, L; Chiarion-Sileni, V; Mohr, P; Karanikolova, TS; Teterycz, P; Espinosa, E; Schnecko, P; Cheng, P; Bender, M; Jiang, S; Burke, T; Ascierto, PA; Gogas, H; Rodas, IM; Rutkowski, P; Schadendorf, D; Dummer, R.

Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe

Cancers. 2024; 16(21): Nº de citas: 1 [doi:10.3390/cancers16213558]

Alonso-Gordoa, T; Jimenez-Fonseca, P; Martinez-Trufero, J; Navarro, M; Porras, I; Rubió-Casadevall, J; Valles, MA; Basté, N; Hernando, J; Docampo, LI.

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(11): 2902-2916 Nº de citas: 1 [doi:10.1007/s12094-024-03736-6]

Arregui M; Calles A; Galera MDM; Gutiérrez A; López-Jiménez C; Agra C; Fernández A; Gutiérrez N; Toro M; Álvarez R.

Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor.

Oncotarget. 2024; 15: 717-724 [doi:10.18632/oncotarget.28654]

Nader-Marta, G; Singer, C; Hlauschek, D; DeMichele, A; Tarantino, P; de Azambuja, E; Pfeiler, G; Martin, M; Balko, JM; Nowecki, Z; Balic, M; Brufsky, AM; Chan, ARE; Morris, PG; Haddad, T; Loibl, S; Liu, Y; Soelkner, L; Fesl, C; Mayer, EL; Gnant, M.

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

BREAST CANCER RESEARCH. 2024; 26(1): Nº de citas: 1 [doi:10.1186/s13058-024-01899-2]

Martín, AJM; Lecumberri, R; Souto, JC; Obispo, B; Sanchez, A; Aparicio, J; Aguayo, C; Gutierrez, D; Palomo, AG; Benavent, D; Taberna, M; Viñuela-Benéitez, MC; Arumi, D; Hernández-Presa, MA.

Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(4): 1816-1825 Nº de citas: 3 [doi:10.1007/s12094-024-03586-2]

Kawazoe, A; Xu, RH; Garcia-Alfonso, P; Passhak, M; Teng, HW; Shergill, A; Gumus, M; Qvortrup, C; Stintzing, S; Towns, K; Kim, TW; Shiu, KK; Cundom, J; Ananda, S; Lebedinets, A; Fu, R; Jain, R; Adelberg, D; Heinemann, V; Yoshino, T; Elez, E.

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(24): Nº de citas: 28 [doi:10.1200/JCO.23.02736]

Cedillo, S; González-Domínguez, A; Ivanova-Markova, Y; López, RL; Cobo, SLT; Pedrosa, JAP.

Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

Pharmacoeconomics-Open. 2024; 8(6): 887-896 [doi:10.1007/s41669-024-00518-2]

Moran, LO; Mateo, FJP; Balanyà, RP; Revuelta, JR; Martinez, SR; Fombella, JPB; Vázquez, EMB; Caro, NL; Langa, JM; Fernández, MS.

SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(11): 2877-2901 Nº de citas: 2 [doi:10.1007/s12094-024-03605-2]

López-Jiménez, C; Gutiérrez, A; Caamaño, DSJ; Alsar, JS; Villa, JLC; Abad, CB; Morón, B; Morán, LO; Martín, M; Martín, AJM.

Impact of COVID-19 in the incidence of venous thromboembolism (VTE) and clinical outcomes in cancer patients: a cohort study

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(2): 756-769 Nº de citas: 1 [doi:10.1007/s12094-024-03635-w]

Lope, V; Guerrero-Zotano, A; de Larrea-Baz, NF; Antolín, S; Viñuales, MB; Bermejo, B; Ruiz-Moreno, E; Baena-Cañada, JM; París, L; Antón, A; Chacón, JI; Muñoz, M; García-Sáenz, JA; Olier, C; Rovira, PS; Lanza, AA; González, S; Brunet, J; Oltra, A; Bezares, S; Rosell, L; Pérez-Gómez, B; Pastor-Barriuso, R; Martín, M; Pollán, M.

Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study

JOURNAL OF NUTRITION HEALTH & AGING. 2024; 28(8): Nº de citas: 1 [doi:10.1016/j.jnha.2024.100312]

Conte, P; Ciruelos, E; Curigliano, G; De Laurentiis, M; Del Mastro, L; Gennari, A; Llombart, A; Martìn, M; Poggio, F; Prat, A; Puglisi, F; Saura, C.

" Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" "

BREAST. 2024; 76: Nº de citas: 4 [doi:10.1016/j.breast.2024.103742]

Curigliano, G; Jimenez, MM; Shimizu, T; Keam, B; Meric-Bernstam, F; Rutten, A; Glaspy, J; Schuler, PJ; Parikh, NS; Ising, M; Hassounah, N; Wu, J; Leyk, M; Chen, X; Burks, H; Chaudhury, A; Otero, J; Cabanas, EG.

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Esmo Open. 2024; 9(8): Nº de citas: 3 [doi:10.1016/j.esmoop.2024.103643]

Chatziioannou, E; Higuita, LMS; Kreft, S; Kandolf, L; Dujovic, B; Reinhardt, L; Tamara, E; Marquez-Rodas, I; Fortuna, ARFP; Nübling, A; Niessner, H; Forschner, A; Garbe, C; Popovic, A; Mirjana, B; Meier, F; Eigentler, T; Leiter, U; Flatz, L; Sinnberg, T; Amaral, T.

Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study

Esmo Open. 2024; 9(8): Nº de citas: 2 [doi:10.1016/j.esmoop.2024.103661]